Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties.

Singh A, Bezuidenhout M, Walsh N, Beirne J, Felletti R, Wang S, Fitzgerald KT, Gallagher WM, Kiely P, Redmond G.

Nanotechnology. 2016 Jul 29;27(30):305603. doi: 10.1088/0957-4484/27/30/305603. Epub 2016 Jun 16.

PMID:
27306338
2.

Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.

Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O'Shea DF.

Nat Commun. 2016 Mar 1;7:10855. doi: 10.1038/ncomms10855.

3.

Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.

Walsh L, Gallagher WM, O'Connor DP, Ní Chonghaile T.

Expert Rev Mol Diagn. 2016 May;16(5):541-51. doi: 10.1586/14737159.2016.1156534. Epub 2016 Mar 16.

PMID:
26895288
4.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.

5.

Prognostic and predictive biomarkers in melanoma: an update.

Foth M, Wouters J, de Chaumont C, Dynoodt P, Gallagher WM.

Expert Rev Mol Diagn. 2016;16(2):223-37. doi: 10.1586/14737159.2016.1126511. Epub 2015 Dec 22.

PMID:
26620320
6.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

PMID:
26541534
7.

The Role of Exosomes in Breast Cancer.

Lowry MC, Gallagher WM, O'Driscoll L.

Clin Chem. 2015 Dec;61(12):1457-65. doi: 10.1373/clinchem.2015.240028. Epub 2015 Oct 14. Review.

PMID:
26467503
8.

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L.

Oncotarget. 2015 Oct 20;6(32):32774-89. doi: 10.18632/oncotarget.5192.

9.

Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.

PMID:
26250344
10.

Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.

O'Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, Lundberg E, Schwenk JM, Jirström K, Bjartell A, Gallagher WM, Uhlén M, Pontén F.

PLoS One. 2015 Aug 3;10(8):e0133449. doi: 10.1371/journal.pone.0133449. eCollection 2015.

11.

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.

Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.

FEBS J. 2015 Sep;282(18):3455-73. doi: 10.1111/febs.13354. Epub 2015 Jul 14.

PMID:
26094870
12.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

PMID:
26030178
13.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

14.

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE.

J Biotechnol. 2015 Jun 20;204:7-12. doi: 10.1016/j.jbiotec.2015.02.036. Epub 2015 Mar 24.

PMID:
25820126
15.

Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.

Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.

Am J Epidemiol. 2015 May 1;181(9):635-47. doi: 10.1093/aje/kwu462. Epub 2015 Mar 19. Review.

16.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
17.

Commercialized biomarkers: new horizons in prostate cancer diagnostics.

Murphy L, Prencipe M, Gallagher WM, Watson RW.

Expert Rev Mol Diagn. 2015 Apr;15(4):491-503. doi: 10.1586/14737159.2015.1011622. Epub 2015 Feb 24. Review.

PMID:
25711191
18.

p53 as a target for the treatment of cancer.

Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM.

Cancer Treat Rev. 2014 Dec;40(10):1153-60. doi: 10.1016/j.ctrv.2014.10.004. Review.

PMID:
25455730
19.

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT.

Br J Cancer. 2014 Dec 9;111(12):2275-86. doi: 10.1038/bjc.2014.529. Epub 2014 Nov 6.

20.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk